March 25, 2025:
The Indianapolis Business Journal (IBJ) and Inside Indiana Business (IIB) recently interviewed Brian Stemme, CEO of Hoosier Cancer Research Network, which serves as the consortium’s administrative headquarters, for separate pieces highlighting the Big Ten Cancer Research Consortium.
The IBJ also interviewed Dr. Nabil Adra, a genitourinary medical oncologist at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center and Big Ten CRC Steering Committee representative for Indiana University.
Both pieces tied into local events this month, as the city of Indianapolis hosted the Big Ten men’s and women’s basketball tournaments.
About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative clinical trials and observational studies that seek to improve the lives of cancer patients in the diverse communities we serve by leveraging the scientific and clinical expertise of Big Ten universities. The Big Ten Cancer Research Consortium creates a unique team research culture to drive science rapidly from ideas to treatment and prevention. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow. Since its founding, the Big Ten CRC has activated nearly 40 clinical trials across a wide range of cancer types, more than 1,000 participants have enrolled in Big Ten CRC studies, and more than 500 researchers have joined Big Ten CRC Clinical Trial Working Groups.
About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness and competitiveness. The broad-based programs of the 18 Big Ten institutions provide direct financial support for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women. For more information, visit www.bigten.org.
December 2, 2024: A Big Ten Cancer Research Consortium (Big Ten CRC) study, BTCRC-LUN16-081, led by Greg Durm, MD, of IU Simon Comprehensive Cancer Center, was published in the Journal of Thoracic Oncology in October 2024. The article is titled, “Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC.” Congratulations to all co-authors and study teams whose hard work led to this publication. Read More
October 1, 2024: The Big Ten Cancer Research Consortium (Big Ten CRC) congratulates Kari Wisinski, MD, on receiving the 2024 Pat Loehrer Award for Exemplary Collaboration in Cancer Research. Read More
March 17, 2025: We are thrilled to reintroduce Across the Consortium, a monthly article showcasing the latest news and events from our member institutions. In this edition, we proudly add our newest member, Fred Hutchinson Cancer Center, which serves as the cancer program for UW Medicine—the University of Washington’s health system—joining our consortium of now 16 institutions. Read More
February 11, 2025: The Big Ten Cancer Research Consortium (Big Ten CRC), a collaboration of the cancer centers of Big Ten Conference universities united to transform cancer research by leveraging their scientific and clinical expertise, welcomed new member Fred Hutch Cancer Center, an independent, nonprofit organization that serves as the cancer program for UW Medicine (the University of Washington’s health system). It is the first new institution to join the consortium following the recent expansion of the Big Ten Conference. Read More
December 17, 2024: A Big Ten Cancer Research Consortium trial, BTCRC-LYM20-463, titled, "A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study," was presented as a poster presentation at the 2024 American Society of Hematology Annual Meeting on December 9, 2024. Congratulations to Vaishalee P Kenkre, MD, of the University of Wisconsin School of Medicine and Public Health, Andrew M Evens, DO, MBA, MSc, of Rutgers Cancer Institute and all co-authors! Read More
December 6, 2024: A Big Ten Cancer Research Consortium (Big Ten CRC) trial titled, “A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042” has been accepted as a poster presentation (P2-07-21) at the 2024 San Antonio Breast Cancer Symposium on December 11, 2024 from 5:30 pm – 7:30 pm. Congratulations to all co-authors and study teams involved in the study! Read More
December 4, 2024: A Big Ten Cancer Research Consortium trial titled, “Alpelisib (BYL719) with continued endocrine therapy following progression on endocrine therapy in hormone receptor–positive, HER2-negative, PIK3CA-mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (BTCRC-BRE19-409)” has been accepted for a poster presentation at the 2024 San Antonio Breast Cancer Symposium on December 11, 2024 from 5:30 pm – 7:00 pm. Congratulations to all co-authors and study teams involved in the study! Read More
December 2, 2024: A Big Ten Cancer Research Consortium (Big Ten CRC) study, BTCRC-LUN16-081, led by Greg Durm, MD, of IU Simon Comprehensive Cancer Center, was published in the Journal of Thoracic Oncology in October 2024. The article is titled, “Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC.” Congratulations to all co-authors and study teams whose hard work led to this publication. Read More
October 1, 2024: The Big Ten Cancer Research Consortium (Big Ten CRC) congratulates Kari Wisinski, MD, on receiving the 2024 Pat Loehrer Award for Exemplary Collaboration in Cancer Research. Read More
March 17, 2025: We are thrilled to reintroduce Across the Consortium, a monthly article showcasing the latest news and events from our member institutions. In this edition, we proudly add our newest member, Fred Hutchinson Cancer Center, which serves as the cancer program for UW Medicine—the University of Washington’s health system—joining our consortium of now 16 institutions. Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube